Tangier Disease

SHANGHAI, June 16, 2023 /PRNewswire/ -- Cholesgen (Shanghai) Co.Ltd. ('Cholesgen') today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca. This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint research effort will leverage complementary strengths and focus on selected targets from Cholesgen's early-stage portfolios. Cholesgen will be entitled to receive an initial payment, as well as a pre-defined license package for each qualified drug candidate nominated by AstraZeneca to progress into clinical development. This programme establishes a new collaboration model with a Chinese biotech, starting from first-in-class targets and mechanisms originally identified by Chinese researchers. Under the governance of a Joint Research Committee, scientists from AstraZeneca and Cholesgen will work closely on target validation and hit generation for the delivery of selected drug candidates, with the priority option for AstraZeneca to bring them into clinical development. High levels of cholesterol are a major risk factor for atherosclerotic cardiovascular disease (ASCVD). ASCVD remains a leading cause of death worldwide, despite advances in preventive interventions. "This is an important collaboration for AstraZeneca, led by deep scientific expertise and a shared ambition to address the key drivers that contribute to hypercholesterolemia and related metabolic diseases. We look forward to working together to accelerate target discovery and preclinical research in this area of high unmet need." said Mene Pangalos, EVP, BioPharmaceuticals R&D, AstraZeneca. "As a young Biotech with deep understanding of target biology and a focused pipeline, Cholesgen is thrilled to start this strategic collaboration with AstraZeneca and hope to accelerate the delivery of innovative medicines for patients with hypercholesterolemia or related metabolic diseases," said Dr. Bao-Liang Song, Chair of SAB Cholesgen. About "Cholesgen" Cholesgen (Shanghai) Co. Ltd. is a biotech pioneering in the biomedical research, innovative target identification and first-in-class drug discovery in the field of cholesterol-related diseases, such as hyperlipidemia, obesity, atherosclerosis, and nonalcoholic steatohepatitis. SOURCE Cholesgen (Shanghai) Co.Ltd.

RMA of New York leads the way with innovative genomics and artificial intelligence research to improve patient care and IVF success rates ANAHEIM, Calif., Oct. 24, 2022 /PRNewswire/ -- Physicians and scientists at RMA of New York (Reproductive Medicine Associates of New York) and the Icahn School of Medicine at Mount Sinai Hospital in New York proudly presented 21 original scientific abstracts at the 78th annual American Society for Reproductive Medicine (ASRM) congress in Anaheim, California. Research topics included live birth outcomes after COVID-19 vaccination, reproductive outcomes following transfer of embryos created from frozen eggs, and access to fertility care for trans- and gender-diverse patients. "The reproductive journey is different now than it was 20 years ago, 10 years ago, and will be months from now. By analyzing big data, accessing machine learning algorithms and artificial intelligence, focusing on genomic and personalized medicine, and ultimately relying on compassionate and consistent clinical care, physicians can improve reproductive outcomes for their patients. We are proud to contribute to science, and look forward to participating in the advancement of the field of reproductive medicine for years to come," said Alan B. Copperman, MD, FACOG, executive director and CEO of RMA of New York, and Director of the Division of Reproductive Endocrinology and Infertility and Clinical Professor of Obstetrics, Gynecology and Reproductive Science at the Icahn Mount Sinai School of Medicine. Nearly two years since the start of the COVID-19 pandemic, the public still has questions about the use of the COVID-19 vaccines in women who are trying to conceive or are pregnant. In a study led by Mount Sinai Reproductive Endocrinologist, Dr. Devora Aharon, the clinical and research team at RMA of New York sought to evaluate any association of COVID-19 mRNA vaccination prior to conception with live birth and neonatal outcomes in patients undergoing IVF. Dr. Aharon and the team found that COVID-19 mRNA vaccination prior to pregnancy is not associated with any impact on live birth rate, probability of premature delivery, or birth weight. This strongly suggests the COVID-19 mRNA vaccination does not have a harmful impact on gestation and neonatal outcomes. This study complements Dr. Aharon's previous research, which demonstrated no correlation between the mRNA COVID-19 vaccines and the implantation rate of euploid embryos. "This is one of the largest studies to review fertility and IVF cycle outcomes in patients who received COVID-19 vaccinations. The study found no significant differences in response to ovarian stimulation, egg quality, embryo development, or pregnancy outcomes between the vaccinated compared to unvaccinated patients," said Devora A. Aharon, MD. "Our findings that vaccination had no impact on these outcomes should be reassuring to those who are trying to conceive, are in early pregnancy, or hope to conceive in the future." Dr. Chelsea Canon, a third-year Fellow, presented novel research providing further insight into the use of cryopreserved oocytes to create embryos for transfer. Her research compared pregnancy outcomes from patients who used embryos developed from fresh oocytes to those of patients who used embryos created with cryopreserved oocytes. Dr. Canon found that ongoing pregnancy and live birth rates do not differ in patients undergoing frozen, single euploid embryo transfers whether their embryo originated from a fresh or cryopreserved oocyte. These results have particular importance as more patients are returning to the clinic to receive treatment and opting to use cryopreserved oocytes to create embryos. Additionally, first-year Fellow Dr. Samantha Estevez presented her work on access to fertility care for trans- and gender-diverse (TGD) patients in the United States. To better understand whether fertility preservation is an established part of hospital services and comprehensive care models, Dr. Estevez and her research team surveyed 654 U.S. hospital websites for evidence of the presence or absence of TGD care. Dr. Estevez's results highlight a significant gap in access to information for TGD-specific fertility care in the U.S. and the critical need for multidisciplinary care to be readily available to TGD patients. RMA of New York is at the forefront of groundbreaking research in infertility and reproductive medicine, and is committed to advancing science for the treatment of infertility. About RMA of New York RMA of New York is widely recognized as a global leader in state-of-the-art reproductive medicine, and serves as the Division of Reproductive Endocrinology and Infertility at the Icahn School of Medicine at Mount Sinai. Led by an integrated team of physicians and scientists with extensive reproductive endocrinology, infertility, and embryology training and experience, RMA of New York is renowned for its pioneering research in the field and for delivering high IVF success rates. For the past 20+ years, the physicians of RMA of New York have consistently been distinguished as Top Doctors and Super Doctors by Castle Connolly and New York Magazine. Headquartered in Midtown Manhattan, RMA of New York has fertility clinic locations throughout Manhattan, Brooklyn, Westchester, Long Island, and abroad in Mexico City. For more information, please visit or find RMA of New York on Instagram, Facebook and Twitter. Media Contact: Pamela Pearlman [email protected] SOURCE RMA of New York

FRAMINGHAM, Mass. , Aug. 17, 2022 /PRNewswire/ -- Boston Heart Diagnostics, part of the Eurofins network of companies, announces the launch of LipidSeq™, a revolutionary genetic test for cardiovascular disease. This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders. These disorders are associated with premature cardiovascular, pancreatic, kidney, and neurological diseases. Continue Reading When patients have very high levels of low-density lipoprotein cholesterol, triglycerides, or plasma sterols and/or very low levels of high-density lipoprotein cholesterol, there is a likelihood of a genetic mutation. Conditions detected by this 23-gene test include familial forms of hypercholesterolemia, lysosomal acid lipase deficiency, sitosterolemia, cerebrotendinous xanthomatosis, dysbetalipoproteinemia, hypertriglyceridemia, and HDL deficiency states including ApoA-I deficiency, Tangier disease, and LCAT deficiency, as well as other disorders. If there is a genetic basis for the patient's condition, understanding the specific mutation and associated disease can help guide treatment considerations, educate the patient about health risks, and encourage relatives to seek testing to determine if they, too, may be at risk. Boston Heart is the only commercial laboratory able to test biochemical and genetic contributors when diagnosing inherited disorders of lipid metabolism (Reference: Schaefer EJ, Geller AS, Endress G. The biochemical and genetic diagnosis of lipid disorders. Current Opinion in Lipidology 2019; 30:56-62.) Boston Heart Diagnostics announces the launch of LipidSeq™, a revolutionary genetic test for cardiovascular disease. Tweet this Testing of appropriate patients can be done at any age, which favors early identification and treatment of genetically influenced lipid and lipoprotein disorders. Early diagnosis and precision treatment can save lives, and have a significant clinical impact for practitioners, patients, and their families. LipidSeq was developed in collaboration with Eurofins laboratory partner Clinical Enterprise, which performs the genetic sequencing, and in consultation with Dr. Robert A. Hegele of Robarts Research Institute in London, Ontario. Healthcare providers may access this testing for their patients by signing up for an account with Boston Heart. The Boston Heart Customer Care department is available at 877.425.1252 or [email protected]. About Boston Heart Diagnostics Corporation Boston Heart Diagnostics, a subsidiary of Eurofins Scientific (EUFI.PA), is transforming the treatment of cardiovascular disease and related conditions by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve health. For more information on Boston Heart Diagnostics, please visit SOURCE Boston Heart Diagnostics